LogicBio Therapeutics Competitors and Similar CompaniesClear all
LogicBio Therapeutics's competitors and similar companies include Immunocore, Agenus, Lexicon Pharmaceuticals and Intellia Therapeutics.
 LogicBio Therapeutics LogicBio Therapeutics develops lifelong cures for serious, early-onset rare diseases by combining gene therapy and gene editing in a one-time treatment. |  Immunocore Immunocore is a T cell receptor (TCR) biotechnology company working to create biological therapies for oncology and infectious and autoimmune diseases. |  Agenus Agenus is an immuno-oncology company that focuses on the discovery and development of therapies for treating cancer. |  Lexicon Pharmaceuticals Lexicon Pharmaceuticals develops therapeutic products for diseases relating to immunology, metabolism, cardiology and ophthalmology. |  Intellia Therapeutics Intellia Therapeutics is a genome editing company that caters to the biotechnology industry. | |
Founding Date | Founding Date 2014 | Founding Date 2008 | Founding Date 1994 | Founding Date 1995 | Founding Date 2014 |
Type | Type Public | Type Public | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations Lexington, US HQ Louisville, US | Locations Milton, GB HQ Conshohocken, US Rockville, US | Locations Lexington, US HQ Cambridge, GB Emeryville, US Berkeley, US Vacaville, US | Locations The Woodlands, US HQ Jersey, JE Atlanta, US Bernards, US Birmingham, US Boston, US Charlotte, US see more | Locations Cambridge, US HQ |
Employees | Employees 4178% increase | Employees 493 | Employees 8174% decrease | Employees 20216% increase | Employees 40323% decrease |
Valuation ($) | Valuation ($) 176.3 m | Valuation ($) 1.6 b | Valuation ($) 96.2 m | Valuation ($) 737.4 m | Valuation ($) 1.7 b |
Financial | |||||
Revenue (est.) | Revenue (est.) $5.4m (FY, 2021) | Revenue (est.) $400m (FY, 2025) | Revenue (est.) $114.2m (FY, 2025) | Revenue (est.) $49.8m (FY, 2025) | Revenue (est.) $67.7m (FY, 2025) |
Cost of goods | Cost of goods N/A | Cost of goods $5.1m (FY, 2025) | Cost of goods $1m (FY, 2025) | Cost of goods $274k (FY, 2025) | Cost of goods N/A |
Gross profit | Gross profit N/A | Gross profit $414.7m (FY, 2025) | Gross profit $113.2m (FY, 2025) | Gross profit $49.5m (FY, 2025) | Gross profit N/A |
Net income | Net income ($40m) (FY, 2021) | Net income ($35.5m) (FY, 2025) | Net income ($3.1m) (FY, 2025) | Net income ($50.3m) (FY, 2025) | Net income ($412.7m) (FY, 2025) |
Funding | |||||
Total funding raised | Total funding raised $ 49m | Total funding raised $ 565m | Total funding raised $ 171.1m | Total funding raised $ 244.7m | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
Immunocore
HQ
Milton, GB
Employees
493
Immunocore is a T cell receptor (TCR) biotechnology company working to create biological therapies for oncology and infectious and autoimmune diseases.
View companyAgenus
HQ
Lexington, US
Employees
81
Agenus is an immuno-oncology company that focuses on the discovery and development of therapies for treating cancer.
View companyLexicon Pharmaceuticals
HQ
The Woodlands, US
Employees
202↑ 16% increase
Lexicon Pharmaceuticals develops therapeutic products for diseases relating to immunology, metabolism, cardiology and ophthalmology.
View companyIntellia Therapeutics
HQ
Cambridge, US
Employees
403↓ 23% decrease
Intellia Therapeutics is a genome editing company that caters to the biotechnology industry.
View company